Literature DB >> 2199127

Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

R K Verbeeck1.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs. Drug interactions with this class of compounds are frequently reported and can be pharmacokinetic and/or pharmacodynamic in nature. The pharmacokinetic interactions can be divided into 3 classes: (1) drugs affecting the pharmacokinetics of an NSAID. (2) an NSAID interfering with the pharmacokinetics of another NSAID and (3) NSAIDs altering the pharmacokinetics of another drug. Although the pharmacokinetics of some NSAIDs may be significantly affected by the concurrent administration of certain other drugs (including other NSAIDs), this type of interaction only occasionally leads to serious complications. Concurrent administration of antacids or sucralfate may delay the rate of oral absorption of NSAIDs but generally has little effect on the extent. Use of antacids increases urinary pH, leading to increased renal excretion of unchanged salicylic acid and decreased plasma concentrations of this antirheumatic agent. The H2-receptor blocking agent cimetidine inhibits the oxidative metabolism of many concurrently administered drugs, including certain NSAIDs. Probenecid inhibits the renal secretion of drug glucuronides and this will lead to accumulation in plasma of those NSAIDs eliminated primarily by the formation of labile acyl glucuronides such as naproxen, ketoprofen, indomethacin, carprofen. Cholestyramine decreases the oral absorption of many concurrently administered drugs, including NSAIDs. It may also decrease plasma concentrations of those NSAIDs undergoing enterohepatic circulation (e.g. piroxicam, tenoxicam) by interrupting the enterohepatic cycle. Corticosteroids stimulate the clearance of salicylic acid, leading to low plasma salicylate concentrations. Plasma concentrations of many NSAIDs are significantly reduced when the NSAID is coadministered with aspirin. The clinical relevance of most of these interactions is not well established. However, in those cases where the interaction results in elevated plasma concentrations of the NSAID, special caution should be exercised to avoid excessive accumulation of the NSAID especially in elderly and/or very sick patients who may be more sensitive to the more serious gastroduodenal and renal side-effects of these agents. By virtue of their pharmacokinetic and pharmacodynamic properties, NSAIDs may significantly affect the disposition kinetics of a number of other drugs. They can displace other drugs from their plasma protein binding sites, inhibit their metabolism or interfere with their renal excretion. If the affected drug has a narrow therapeutic index, the interaction may be clinically significant. The pyrazole NSAIDs (phenylbutazone, oxyphenbutazone, azapropazone) inhibit the metabolism of many drugs such as the coumarin anticoagulants, oral antidiabetics and anticonvulsants such as phenytoin. Salicylates displace oral anticoagulants from their plasma protein binding sites.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199127     DOI: 10.2165/00003088-199019010-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  222 in total

1.  Folic acid deficiency and epilepsy.

Authors:  J W Norris; R F Pratt
Journal:  Drugs       Date:  1974       Impact factor: 9.546

2.  Effect of food and various antacids on the absorption of tenoxicam.

Authors:  R O Day; S Lam; P Paull; D Wade
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

3.  Possible toxic interaction between lithium and piroxicam.

Authors:  R J Kerry; G Owen; S Michaelson
Journal:  Lancet       Date:  1983-02-19       Impact factor: 79.321

4.  [Study on possible interactions between tiaprofenic acid and phenprocoumon (author's transl)].

Authors:  J Dürr; M H Pfeiffer; B Penth; K Wetzelsberger; P W Lücker
Journal:  Arzneimittelforschung       Date:  1981

Review 5.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

6.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

7.  Effect of antacid and ascorbic acid on serum salicylate concentration.

Authors:  P D Hansten; W L Hayton
Journal:  J Clin Pharmacol       Date:  1980 May-Jun       Impact factor: 3.126

Review 8.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

9.  The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study.

Authors:  N Baber; L Halliday; R Sibeon; T Littler; M L Orme
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

10.  Evaluation of a potential drug interaction between sucralfate and aspirin.

Authors:  A H Lau; C W Chang; P K Schlesinger
Journal:  Clin Pharmacol Ther       Date:  1986-02       Impact factor: 6.875

View more
  28 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 2.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats.

Authors:  E Tigka; I Daskala; G Rallis; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

4.  Lack of interaction between meloxicam and warfarin in healthy volunteers.

Authors:  D Türck; C A Su; G Heinzel; U Busch; E Bluhmki; J Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

5.  Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers.

Authors:  G Apseloff; K D Wilner; N Gerber
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

Review 6.  Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats.

Authors:  K A Mathews
Journal:  Can Vet J       Date:  1996-09       Impact factor: 1.008

Review 7.  The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism.

Authors:  Basil Rigas; George J Tsioulias
Journal:  J Pharmacol Exp Ther       Date:  2015-04       Impact factor: 4.030

8.  Prinomide tromethamine pharmacokinetics: mutually dependent saturable and competitive protein binding between prinomide and its own metabolite.

Authors:  G M Kochak; S Pai; R Iannucci; F Honc; D Kachmar; P Perrino; H Egger
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

9.  Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta.

Authors:  D B Hogan; N R Campbell; R Crutcher; P Jennett; N MacLeod
Journal:  CMAJ       Date:  1994-08-01       Impact factor: 8.262

10.  A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure.

Authors:  E Baggio; F Maraffi; C Montalto; M L Nava; L Torti; I Casciarri
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.